Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Clinical trial NCT05422222 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05422222
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-21
- Primary completion
- 2030-06-30
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.